{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:37:54Z","timestamp":1774330674804,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s40272-025-00692-8","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:37:38Z","timestamp":1742009858000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Macitentan: Pediatric First Approval"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-7645","authenticated-orcid":false,"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"1","key":"692_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/ehjqcco\/qcad020","volume":"10","author":"MJ Ploegstra","year":"2024","unstructured":"Ploegstra MJ, Ivy DD, Beghetti M, et al. Long-term outcome of children with newly diagnosed pulmonary arterial hypertension: results from the global TOPP registry. Eur Heart J Qual Care Clin Outcomes. 2024;10(1):66\u201376.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"38","key":"692_CR2","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618\u2013731.","journal-title":"Eur Heart J"},{"key":"692_CR3","unstructured":"Janssen-Cilag International NV. Macitentan: EU prescribing information. 2024. https:\/\/www.ema.europa.eu\/. Accessed 20 Dec 2024."},{"issue":"17","key":"692_CR4","doi-asserted-by":"publisher","first-page":"7849","DOI":"10.1021\/jm3009103","volume":"55","author":"MH Bolli","year":"2012","unstructured":"Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2019-propylsulfamide (macitentan), an orally active, potent dual endothelin receptor antagonist. J Med Chem. 2012;55(17):7849\u201361.","journal-title":"J Med Chem"},{"issue":"6","key":"692_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s40256-016-0188-x","volume":"16","author":"GM Keating","year":"2016","unstructured":"Keating GM. Macitentan: a review in pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2016;16(6):453\u201360.","journal-title":"Am J Cardiovasc Drugs"},{"key":"692_CR6","doi-asserted-by":"publisher","first-page":"4374","DOI":"10.1007\/s12325-022-02199-x","volume":"39","author":"R Souza","year":"2022","unstructured":"Souza R, Delcroix M, Galie N, et al. Long-term safety, tolerability and survival in patients with pulmonary arterial hypertension treated with macitentan: results from the SERAPHIN open-label extension. Adv Ther. 2022;39:4374\u201390.","journal-title":"Adv Ther"},{"key":"692_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12150","author":"VV McLaughlin","year":"2022","unstructured":"McLaughlin VV, Channick R, Kim NH, et al. Safety of macitentan for the treatment of pulmonary hypertension: real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS). Pulm Circ. 2022. https:\/\/doi.org\/10.1002\/pul2.12150.","journal-title":"Pulm Circ."},{"issue":"9","key":"692_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318.","journal-title":"N Engl J Med"},{"key":"692_CR9","unstructured":"European Commission. Union register of medical products for human use: Opsumit. 2024. https:\/\/ec.europa.eu\/health\/documents\/community-register\/html\/h893.htm. Accessed 28 Jan 2025."},{"key":"692_CR10","unstructured":"European Medicines Agency. Assessment report on a group of an extension of marketing authorisation and an extension of indication variation: Opsumit (Macitentan). EMA\/389480\/2024. 2024(Procedure No. EMEA\/H\/C\/002697\/X\/0051\/G):1-178."},{"key":"692_CR11","unstructured":"Janssen-Cilag Ltd (a Johnson & Johnson Company). Macitentan 10 mg film-coated tablets: UK summary of product characteristics. 2024. https:\/\/products.mhra.gov.uk\/. Accessed 10 Feb 2025."},{"key":"692_CR12","unstructured":"Janssen-Cilag Ltd (a Johnson & Johnson Company). Macitentan 2.5 mg dispersible tablets: UK summary of product characteristics. 2024. https:\/\/products.mhra.gov.uk\/. Accessed 12 Feb 2025."},{"key":"692_CR13","unstructured":"Johnson & Johnson. Use of OPSUMIT in pediatrics with WHO Group I pulmonary hypertension. 2024. https:\/\/www.jnjmedicalconnect.com\/. Accessed 20 Dec 2025."},{"issue":"4","key":"692_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40272-023-00573-y","volume":"25","author":"S Albinni","year":"2023","unstructured":"Albinni S, Heno J, Pavo I, et al. Macitentan in the young: mid-term outcomes of patients with pulmonary hypertensive vascular disease treated in a pediatric tertiary care center. Paediatr Drugs. 2023;25(4):467\u201381.","journal-title":"Paediatr Drugs"},{"issue":"5","key":"692_CR15","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.21037\/cdt.2020.04.01","volume":"10","author":"S Schweintzger","year":"2020","unstructured":"Schweintzger S, Koestenberger M, Schlagenhauf A, et al. Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension. Cardiovasc Diagn Ther. 2020;10(5):1675\u201385.","journal-title":"Cardiovasc Diagn Ther."},{"issue":"5","key":"692_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1017\/S1047951120000773","volume":"30","author":"E Aypar","year":"2020","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, et al. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension: extended study results. Cardiol Young. 2020;30(5):681\u20135.","journal-title":"Cardiol Young"},{"issue":"4","key":"692_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1017\/S1047951117002542","volume":"28","author":"E Aypar","year":"2018","unstructured":"Aypar E, Alehan D, Karag\u00f6z T, et al. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension. Cardiol Young. 2018;28(4):542\u20137.","journal-title":"Cardiol Young"},{"issue":"1","key":"692_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pedneo.2023.12.007","volume":"66","author":"M Kashaki","year":"2024","unstructured":"Kashaki M, Mohazzab A, Radgoudarzi M, et al. Study on the comparison between bosentan and macitentan in the treatment of persistent pulmonary hypertension of the newborns, simultaneously on sildenafil: a randomized double-blinded non-inferiority parallel clinical trial. Pediatr Neonatol. 2024;66(1):44\u20139.","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"692_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045894020979503","volume":"11","author":"S Albinni","year":"2021","unstructured":"Albinni S, Pavo I, Kitzmueller E, et al. Macitentan in infants and children with pulmonary hypertensive vascular disease. Feasibility, tolerability and practical issues\u2014a single-centre experience. Pulm Circ. 2021;11(1):1\u201310.","journal-title":"Pulm Circ."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00692-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T11:27:55Z","timestamp":1745580475000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00692-8","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"15 March 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}